At a glance
ClinicalIndex Comparison RecordPhase 2Active· 40 enrolled / 40 target
Drug / intervention
Rapamycin +1 moredrug
Likely dose
Rapamycin 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)
The University of Texas Health Science Center at San Antonio·interventional·Posted Nov 16, 2020·Updated Jun 9, 2026
In Brief
A Phase 2 clinical trial evaluating Rapamycin and Placebo for Mild Cognitive Impairment and Alzheimer Disease. Active but no longer recruiting, targeting 40 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, Alzheimer Disease
CountriesUnited States
CollaboratorsAlzheimer's Association
Timeline
Phase 2Active
2021202220232024202520262027
First PostedNov 2020
Enrollment StartAug 2021
Primary CompletionMar 2026
TodayJul 2026
Study CompletionMar 2027
First PostedNov 16, 2020
Enrollment StartAug 11, 2021
Primary CompletionMar 5, 2026
Study CompletionMar 5, 2027
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 5.6 years ago
Arms & Interventions
RAPA (rapamycin) treatment groupactive_comparator
Subjects will receive active drug
Drug: Rapamycin
Placebo groupplacebo_comparator
Subjects will receive placebo
Other: Placebo
Interventions
Rapamycindrug
RAPA will be administered orally 1mg daily
Placeboother
Placebo will be administered orally once daily